Healthcare / Drug Manufacturers - Specialty & GenericBSE
$115.10
-6.70 (-5.50%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 19%
FCF escenarios
weak_data · normalized FCF $258.5M · quality 36.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
38/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.5B
P/E
26.5x
↑EV/EBITDA
9.2x
↓ROE
6.8%
↑Gross Margin
66.4%
↑Debt/Equity
1.11
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+3.8%
FCF CAGR
—
FCF margin
-11.0%
FCF / Net income
-2.13x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.88B · net income $148.8M · FCF $-317.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.88B | $2.88B | $2.75B | $2.78B | $2.58B |
| Net Income | $148.8M | $148.8M | $105.0M | $36.3M | $-21.1M |
| EBITDA | $606.0M | $606.0M | $610.5M | $575.2M | $554.2M |
| EPS | 4.33 | 4.33 | 2.70 | 0.94 | -0.54 |
| Gross Margin | 66.4% | 66.4% | 65.8% | 60.6% | 59.0% |
| Operating Margin | 14.3% | 14.3% | 15.0% | 13.8% | 13.5% |
| Net Margin | 5.2% | 5.2% | 3.8% | 1.3% | -0.8% |
| Balance Sheet | |||||
| Debt/Equity | 1.11 | 1.11 | 2.00 | 3.02 | 3.40 |
| Current Ratio | 1.69 | 1.69 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-317.4M | $-317.4M | $258.5M | $446.6M | $362.9M |
| Returns | |||||
| ROE | 6.8% | 6.8% | 10.9% | 5.5% | -3.4% |
| Valuation | |||||
| P/E | 26.52 | 26.52 | — | — | — |
| EV/EBITDA | 9.22 | 9.22 | — | — | — |
| P/B | 1.80 | 1.80 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | 4.7% | 4.7% | -1.3% | 8.1% | — |
| EPS Growth | 60.1% | 60.1% | 189.0% | 272.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
33.1%
EPS terminal req.
$10.21
Spread vs growth
27.0%
5Y implied EPS CAGR
23.3%
EPS terminal req.
$12.36
Spread vs growth
36.8%
10Y implied EPS CAGR
16.5%
EPS terminal req.
$19.90
Spread vs growth
43.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-18.2%
Start / end P/E
52.0x → 26.6x
EPS bridge
2.70 → 4.33
Residual
-29.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.